News in other languages: NEOVACS

15/06	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
22/05	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
22/05	L'IA reprend le leadership
04/05	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
04/05	Coup de théâtre ou coup d'épée dans l'eau ?

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.48%	+7.20%	-5.08%	+2.45%	4.64TCr
REVOLUTION MEDICINES, INC.	+0.56%	+8.03%	+377.93%	+620.27%	3.79TCr
IQVIA HOLDINGS INC.	+1.46%	+12.87%	+19.75%	-11.42%	3.11TCr
BEONE MEDICINES AG	+1.08%	+2.20%	+9.15%	+54.24%	3.06TCr
CELLTRION, INC.	-4.16%	-4.44%	+8.53%	+16.06%	2.47TCr
ASCENDIS PHARMA A/S	-0.87%	+13.18%	-	-	1.62TCr
MEDPACE HOLDINGS, INC.	+0.82%	+14.95%	+70.72%	+132.67%	1.48TCr
EUROFINS SCIENTIFIC SE	+1.00%	+10.30%	+13.31%	+22.84%	1.36TCr
IONIS PHARMACEUTICALS, INC.	+2.53%	+5.94%	+102.11%	+105.63%	1.29TCr
Average	+0.24%	+7.85%	+74.55%	+117.84%	2.54TCr
Weighted average by Cap.	+0.07%	+7.66%	+83.66%	+136.57%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	4.09T 4.66T 3.77T 3.53T 6.62T 4L 6.75T 45.3T 17.53T 2L 17.51T 17.13T 8L	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-2L -2L -2L -2L -3L -2.16Cr -3L -22.27L -9L -1.07Cr -9L -8L -3.71Cr	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	0.01%	Yield 2023 *	-	Yield 2024	-

11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/25/21	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/25/12	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/25/30	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/25/30	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/25/17	Neovacs S.A. announced a financing transaction	CI
04/25/04	Neovacs: consideration of delisting, share price surges
04/24/04	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/24/01	Tech's Tangled Path with Microsoft
17/24/17	Neovacs: collaboration agreement with CNRS
10/24/10	Neovacs: presents results from vaccine candidates
04/24/04	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

	2023	2024
Net sales	5L 6L 5L 5L 9L 5.74Cr 9L 59.1L 22.87L 2.84Cr 22.84L 22.35L 9.83Cr	4L 5L 4L 4L 7L 4.67Cr 7L 48.08L 18.6L 2.31Cr 18.58L 18.18L 8Cr
Net income	-87.43L -99.72L -80.59L -75.45L -1.41Cr -94Cr -1.44Cr -9.69Cr -3.75Cr -46Cr -3.74Cr -3.66Cr -161.21Cr	-3.29Cr -3.75Cr -3.03Cr -2.84Cr -5.33Cr -354.12Cr -5.44Cr -36Cr -14Cr -175.01Cr -14Cr -14Cr -606.87Cr
Net Debt	-2L -3L -2L -2L -4L -2.54Cr -4L -26.2L -10.14L -1.26Cr -10.13L -10L -4.36Cr	-2L -2L -2L -2L -3L -2.21Cr -3L -22.72L -9L -1.09Cr -9L -9L -3.78Cr

NEOVACS Share Price Xetra

Stocks

0LW

FR0004032746

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile

End-of-day quote Xetra Other stock markets
- ^EUR	-